Table 4.

Multivariate analysis of mortality and DMFP risk factors and SLC39A6/GATA3.

	Overall survival		Distant metastasis-free probability
	Hazard ratio (95% confidence interval)	p-value	Hazard ratio (95% confidence interval)	p-value
SLC39A6/GATA3: Group 2 vs. Group 1	1.557 (0.7914 – 3.061)	0.2000	1.208 (0.621 – 2.347)	0.5800
SLC39A6/GATA3: Group 3 vs. Group 1	1.675 (0.9739 – 2.882)	0.0620	1.207 (0.715 – 2.038)	0.4800
Age (decade)	0.678 (0.4722 – 0.973)	0.0350	0.720 (0.513 – 1.011)	0.0580
Tumor diameter (cm)	1.022 (0.9964 – 1.048)	0.0940	1.033 (1.009 – 1.058)	0.0067
Lymph node status (positive node)	1.019 (0.8396 – 1.237)	0.8500	1.054 (0.894 – 1.241)	0.5300
Tumor grade: Poorly diff. vs. Intermediate	1.403 (0.7994 – 2.463)	0.2400	1.117 (0.657 – 1.901)	0.6800
Tumor grade: Well diff. vs. Intermediate	0.222 (0.0769 – 0.643)	0.0055	0.381 (0.180 – 0.806)	0.0120
Vascular invasion: 1–3 vessels vs. ≥ 4 vessels	0.678 (0.2352 – 1.956)	0.4700	0.577 (0.217 – 1.532)	0.2700
Vascular invasion: 0 vessels vs. ≥ 4 vessels	0.638 (0.1456 – 2.794)	0.5500	0.597 (0.157 – 2.263)	0.4500
Mastectomy vs. breast conserving therapy	1.078 (0.6682 – 1.738)	0.7600	1.165 (0.733 – 1.851)	0.5200
Chemo and hormonal therapy v. no adjuvant therapy	0.718 (0.3291 – 1.567)	0.4100	0.496 (0.245 – 1.005)	0.0510

Results of the multivariate analysis of mortality risk factors (left) and DMFP risk factors (right). The group classifications determined by the SLC39A6 and GATA3 (Hs.524134) gene pair are included. The p-values less than 0.05 are in bold. The p-values significant at an α = 0.10 level but not at an α = 0.05 significance level are in italics.